Middle East & Africa Cancer Drugs Market Size and Forecast (2021 - 2031)
The Middle East and Africa (MEA) Cancer Drugs Market is projected to grow significantly, reaching an estimated US$ 8,816.2 million by 2031, up from US$ 4,415.8 million in 2024. This growth represents a compound annual growth rate (CAGR) of 10.4% from 2025 to 2031, driven by various factors including increasing cancer incidence, advancements in healthcare infrastructure, and the adoption of precision medicine.
Executive Summary and Market Analysis
The MEA region, particularly Turkey, the Gulf Cooperation Council (GCC) countries, and South Africa, leads in cancer drug sales. The rise in cancer cases is attributed to an aging population, urbanization, lifestyle changes, and improvements in healthcare systems, especially in the GCC and urban centers in South Africa. The trend towards precision medicine, which utilizes genetic profiling and biomarker-driven therapies, is becoming more prevalent in oncology practices across the region.
Government initiatives and regulatory reforms in GCC countries are facilitating quicker access to innovative cancer treatments. Additionally, the promotion of biosimilars and generics by government bodies aims to enhance the affordability of cancer medications. Strategic partnerships, such as Pharmalink's collaboration to commercialize sugemalimab in the MEA, are also strengthening the precision oncology pipeline.
Digital health innovations are playing a crucial role in improving access to cancer care, particularly in underserved areas of Sub-Saharan Africa. Platforms like Discovery Health in South Africa and Babylon Health in Kenya are pioneering telemedicine, AI triage, symptom tracking, and remote consultations, making cancer care more accessible.
Market Segmentation Analysis
The MEA Cancer Drugs Market is segmented by therapy types, indications, and distribution channels:
The cancer drugs market is undergoing a significant transformation, largely due to the increasing preference for personalized medicine. This approach tailors treatments to the individual patient's molecular, genetic, and biomarker profiles. Technological advancements, particularly in next-generation sequencing (NGS), have reduced the costs and time required for tumor genome profiling, allowing for more precise targeting of therapies.
Companion diagnostics are becoming integral to clinical trial designs and routine oncology care, helping to identify actionable mutations and biomarkers. This shift has spurred innovation in therapeutic offerings, with tissue-agnostic drugs like pembrolizumab and entrectinib being approved based on shared genetic mutations rather than tumor types. Such advancements exemplify the move towards individualized cancer care.
Other personalized approaches, including functional drug sensitivity testing and patient-derived xenograft (PDX) models, are gaining traction, enabling clinicians to predict treatment responses more accurately. For instance, NIH researchers have developed a personalized cancer therapy that utilizes a patient’s immune cells to combat metastatic cancer. Both public and private sectors are increasing investments in biomarker-driven therapies and precision diagnostics, with major pharmaceutical companies forming collaborations to expedite the development of precision drug pipelines.
Artificial intelligence and machine learning are also enhancing drug design and patient stratification, leading to more efficient and effective personalized clinical trials. As a result, personalized medicine is expected to emerge as a significant growth trend in the cancer drug market during the forecast period.
Country Insights
The MEA Cancer Drugs Market is further segmented by country, including Turkey, GCC countries, South Africa, and the Rest of the Middle East and Africa. South Africa is anticipated to hold the largest market share in 2024.
Cancer remains a leading cause of death in South Africa, with prevalent types including breast, prostate, cervical, and lung cancer. According to GLOBOCAN data, approximately 108,168 new cancer cases were diagnosed in 2020, with 56,802 cancer-related deaths. The South African government is actively addressing the rising cancer burden through various initiatives aimed at improving access to cancer care and encouraging innovations in cancer therapies. National health policies are focused on enhancing cancer diagnosis and treatment, with the National Health Insurance (NHI) proposal aiming to provide comprehensive healthcare coverage, including cancer treatment, to all citizens.
Company Profiles
Key players in the MEA Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
Executive Summary and Market Analysis
The MEA region, particularly Turkey, the Gulf Cooperation Council (GCC) countries, and South Africa, leads in cancer drug sales. The rise in cancer cases is attributed to an aging population, urbanization, lifestyle changes, and improvements in healthcare systems, especially in the GCC and urban centers in South Africa. The trend towards precision medicine, which utilizes genetic profiling and biomarker-driven therapies, is becoming more prevalent in oncology practices across the region.
Government initiatives and regulatory reforms in GCC countries are facilitating quicker access to innovative cancer treatments. Additionally, the promotion of biosimilars and generics by government bodies aims to enhance the affordability of cancer medications. Strategic partnerships, such as Pharmalink's collaboration to commercialize sugemalimab in the MEA, are also strengthening the precision oncology pipeline.
Digital health innovations are playing a crucial role in improving access to cancer care, particularly in underserved areas of Sub-Saharan Africa. Platforms like Discovery Health in South Africa and Babylon Health in Kenya are pioneering telemedicine, AI triage, symptom tracking, and remote consultations, making cancer care more accessible.
Market Segmentation Analysis
The MEA Cancer Drugs Market is segmented by therapy types, indications, and distribution channels:
- By Therapy Types: The market includes Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, and Other Therapy Types. Targeted Therapy is the leading segment as of 2024.
- By Indications: The market is categorized into Blood Cancer, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Ducts Cancer, Thyroid Cancer, and Other Indications. The Other Indications segment was the largest in 2024.
- By Distribution Channel: The market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Stores, with Hospital Pharmacies dominating the market in 2024.
The cancer drugs market is undergoing a significant transformation, largely due to the increasing preference for personalized medicine. This approach tailors treatments to the individual patient's molecular, genetic, and biomarker profiles. Technological advancements, particularly in next-generation sequencing (NGS), have reduced the costs and time required for tumor genome profiling, allowing for more precise targeting of therapies.
Companion diagnostics are becoming integral to clinical trial designs and routine oncology care, helping to identify actionable mutations and biomarkers. This shift has spurred innovation in therapeutic offerings, with tissue-agnostic drugs like pembrolizumab and entrectinib being approved based on shared genetic mutations rather than tumor types. Such advancements exemplify the move towards individualized cancer care.
Other personalized approaches, including functional drug sensitivity testing and patient-derived xenograft (PDX) models, are gaining traction, enabling clinicians to predict treatment responses more accurately. For instance, NIH researchers have developed a personalized cancer therapy that utilizes a patient’s immune cells to combat metastatic cancer. Both public and private sectors are increasing investments in biomarker-driven therapies and precision diagnostics, with major pharmaceutical companies forming collaborations to expedite the development of precision drug pipelines.
Artificial intelligence and machine learning are also enhancing drug design and patient stratification, leading to more efficient and effective personalized clinical trials. As a result, personalized medicine is expected to emerge as a significant growth trend in the cancer drug market during the forecast period.
Country Insights
The MEA Cancer Drugs Market is further segmented by country, including Turkey, GCC countries, South Africa, and the Rest of the Middle East and Africa. South Africa is anticipated to hold the largest market share in 2024.
Cancer remains a leading cause of death in South Africa, with prevalent types including breast, prostate, cervical, and lung cancer. According to GLOBOCAN data, approximately 108,168 new cancer cases were diagnosed in 2020, with 56,802 cancer-related deaths. The South African government is actively addressing the rising cancer burden through various initiatives aimed at improving access to cancer care and encouraging innovations in cancer therapies. National health policies are focused on enhancing cancer diagnosis and treatment, with the National Health Insurance (NHI) proposal aiming to provide comprehensive healthcare coverage, including cancer treatment, to all citizens.
Company Profiles
Key players in the MEA Cancer Drugs Market include F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, AstraZeneca Plc, Astellas Pharma Inc, AbbVie Inc, Merck KGaA, and Eli Lilly and Co. These companies are employing strategies such as expansion, product innovation, and mergers and acquisitions to enhance their market presence and offer innovative products to consumers.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CANCER DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.4 List of Vendors in the Value Chain
5. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CANCER DRUGS MARKET - MIDDLE EAST AND AFRICA MARKET ANALYSIS
6.1 Middle East and Africa Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
6.2 Middle East and Africa Cancer Drugs Market Forecast and Analysis
7. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY THERAPY TYPES
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY INDICATIONS
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET – COUNTRY ANALYSIS
10.1 Middle East and Africa
10.1.1 Middle East and Africa Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Middle East and Africa Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.2.2 Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 Turkey: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.1.2.2.2 Turkey: Middle East and Africa Cancer Drugs Market Share – by Indications
10.1.2.2.3 Turkey: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.2.3.3 GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.2.3.3.2 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Indications
10.2.3.3.3 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.3.4.4 South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 South Africa: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.3.4.4.2 South Africa: Middle East and Africa Cancer Drugs Market Share – by Indications
10.3.4.4.3 South Africa: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.4.5.5 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.4.5.5.2 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Indications
10.4.5.5.3 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Novartis AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson & Johnson
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AstraZeneca Plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Astellas Pharma Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AbbVie Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Merck KGaA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Eli Lilly and Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CANCER DRUGS MARKET LANDSCAPE
4.1 Market Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.4 List of Vendors in the Value Chain
5. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CANCER DRUGS MARKET - MIDDLE EAST AND AFRICA MARKET ANALYSIS
6.1 Middle East and Africa Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
6.2 Middle East and Africa Cancer Drugs Market Forecast and Analysis
7. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY THERAPY TYPES
7.1 Chemotherapy
7.1.1 Overview
7.1.2 Chemotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.2 Targeted Therapy
7.2.1 Overview
7.2.2 Targeted Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.3 Immunotherapy
7.3.1 Overview
7.3.2 Immunotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.4 Hormonal Therapy
7.4.1 Overview
7.4.2 Hormonal Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
7.5 Other Therapy Types
7.5.1 Overview
7.5.2 Other Therapy Types: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY INDICATIONS
8.1 Blood Cancer
8.1.1 Overview
8.1.2 Blood Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.2 Lung Cancer
8.2.1 Overview
8.2.2 Lung Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.3 Breast Cancer
8.3.1 Overview
8.3.2 Breast Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.4 Colorectal Cancer
8.4.1 Overview
8.4.2 Colorectal Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.5 Prostate Cancer
8.5.1 Overview
8.5.2 Prostate Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.6 Stomach Cancer
8.6.1 Overview
8.6.2 Stomach Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.7 Cervical Cancer
8.7.1 Overview
8.7.2 Cervical Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.8 Liver and Intrahepatic Bile Ducts Cancer
8.8.1 Overview
8.8.2 Liver and Intrahepatic Bile Ducts Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.9 Thyroid Cancer
8.9.1 Overview
8.9.2 Thyroid Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
8.10 Other Indications
8.10.1 Overview
8.10.2 Other Indications: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET REVENUE ANALYSIS – BY DISTRIBUTION CHANNEL
9.1 Hospital Pharmacies
9.1.1 Overview
9.1.2 Hospital Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.2 Retail Pharmacies
9.2.1 Overview
9.2.2 Retail Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
9.3 Online Stores
9.3.1 Overview
9.3.2 Online Stores: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10. MIDDLE EAST AND AFRICA CANCER DRUGS MARKET – COUNTRY ANALYSIS
10.1 Middle East and Africa
10.1.1 Middle East and Africa Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.1.1 Middle East and Africa Cancer Drugs Market Revenue and Forecast and Analysis – by Country
10.1.2.2 Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.1.2.2.1 Turkey: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.1.2.2.2 Turkey: Middle East and Africa Cancer Drugs Market Share – by Indications
10.1.2.2.3 Turkey: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.2.3.3 GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.2.3.3.1 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.2.3.3.2 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Indications
10.2.3.3.3 GCC Countries: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.3.4.4 South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.3.4.4.1 South Africa: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.3.4.4.2 South Africa: Middle East and Africa Cancer Drugs Market Share – by Indications
10.3.4.4.3 South Africa: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
10.4.5.5 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
10.4.5.5.1 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Therapy Types
10.4.5.5.2 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Indications
10.4.5.5.3 Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market Share – by Distribution Channel
11 COMPETITIVE LANDSCAPE
11.1 Heat Map Analysis by Key Players
11.2 Company Positioning & Concentration
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 F. Hoffmann-La Roche Ltd
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Pfizer Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Novartis AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Bristol-Myers Squibb Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Johnson & Johnson
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 AstraZeneca Plc
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Astellas Pharma Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 AbbVie Inc
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 Merck KGaA
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Eli Lilly and Co
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East and Africa Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 5. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 6. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 7. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 9. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 10. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 11. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 12. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 13. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 14. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 15. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 16. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 17. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 18. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 19. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 20. Heat Map Analysis by Key Players
Table 1. Middle East and Africa Cancer Drugs Market Segmentation
Table 2. List of Vendors
Table 3. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Table 4. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 5. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 6. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 7. Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Country
Table 8. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 9. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 10. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 11. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 12. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 13. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 14. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 15. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 16. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 17. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Therapy Types
Table 18. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Indications
Table 19. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Distribution Channel
Table 20. Heat Map Analysis by Key Players
LIST OF FIGURES
Figure 1. Middle East and Africa Cancer Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Cancer Drugs Market
Figure 4. Middle East and Africa Cancer Drugs Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East and Africa Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
Figure 7. Middle East and Africa Cancer Drugs Market Share (%) – by Therapy Types, 2024 and 2031
Figure 8. Chemotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Targeted Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Hormonal Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Other Therapy Types: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Middle East and Africa Cancer Drugs Market Share (%) – by Indications, 2024 and 2031
Figure 14. Blood Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. Lung Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Breast Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Colorectal Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 18. Prostate Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Stomach Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Cervical Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Liver and Intrahepatic Bile Ducts Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Thyroid Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 23. Other Indications: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. Middle East and Africa Cancer Drugs Market Share (%) – by Distribution Channel, 2024 and 2031
Figure 25. Hospital Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Retail Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Online Stores: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Middle East and Africa Cancer Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 29. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 30. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 31. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 32. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 33. Company Positioning & Concentration
Figure 1. Middle East and Africa Cancer Drugs Market Segmentation – Country
Figure 2. PEST Analysis
Figure 3. Ecosystem: Cancer Drugs Market
Figure 4. Middle East and Africa Cancer Drugs Market – Key Market Dynamics
Figure 5. Impact Analysis of Drivers and Restraints
Figure 6. Middle East and Africa Cancer Drugs Market Revenue (US$ Million), 2024 – 2031
Figure 7. Middle East and Africa Cancer Drugs Market Share (%) – by Therapy Types, 2024 and 2031
Figure 8. Chemotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 9. Targeted Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 10. Immunotherapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 11. Hormonal Therapy: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 12. Other Therapy Types: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 13. Middle East and Africa Cancer Drugs Market Share (%) – by Indications, 2024 and 2031
Figure 14. Blood Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 15. Lung Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 16. Breast Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 17. Colorectal Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 18. Prostate Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 19. Stomach Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 20. Cervical Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 21. Liver and Intrahepatic Bile Ducts Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 22. Thyroid Cancer: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 23. Other Indications: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 24. Middle East and Africa Cancer Drugs Market Share (%) – by Distribution Channel, 2024 and 2031
Figure 25. Hospital Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 26. Retail Pharmacies: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 27. Online Stores: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 28. Middle East and Africa Cancer Drugs Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 29. Turkey: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 30. GCC Countries: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 31. South Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 32. Rest of Middle East and Africa: Middle East and Africa Cancer Drugs Market – Revenue and Forecast, 2021 – 2031 (US$ Million)
Figure 33. Company Positioning & Concentration
